Evidence map›Paper›PMID 42712373›Full record

Observational studyFrontiers in immunology2026

Maternal microchimerism accelerates immune tolerance induction to factor VIII in children with hemophilia A and FVIII inhibitors.

Zekun Li, Yeling Lu, Zhenping Chen, Jing Dai, Xi Wu, Xiaohong Cai, Xiaorong Pan, Siyu Cai, Gang Li, Xiaoling Cheng and 6 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zekun Li *Hemophilia Comprehensive Care Center, Haematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yeling Lu *Clinical Laboratory Medicine Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhenping Chen *Cell and Gene Therapy Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jing DaiClinical Laboratory Medicine Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xi WuClinical Laboratory Medicine Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiaohong CaiBlood Transfusion Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiaorong PanFaculty of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Siyu CaiCenter for Clinical Epidemiology and Evidence-based Medicine, Capital Medical University, Beijing, China.
Gang LiCell and Gene Therapy Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Xiaoling ChengDepartment of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Di AiHemophilia Comprehensive Care Center, Haematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jialu ZhangHemophilia Comprehensive Care Center, Haematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Qiulan DingClinical Laboratory Medicine Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Wenman WuClinical Laboratory Medicine Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xuefeng WangClinical Laboratory Medicine Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Runhui WuHemophilia Comprehensive Care Center, Haematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Predictors for the successful eradication of neutralizing anti-FVIII alloantibodies (inhibitors) in hemophilia A patients receiving immune tolerance induction (ITI) therapy remain limited. Maternal microchimerism (MMc) showed potential to protect hemophilia A patients from inhibitor development. Objectives: To investigated the role of MMc in ITI therapy. Patients/Methods: This observational study enrolled 121 pediatric with hemophilia A and inhibitors. MMc was determined using droplet digital PCR. Low-dose ITI (FVIII ~50IU/kg every other day) was administered, with adjunctive rituximab given to patients with higher risk clinical features. Results: Of the 101 patients evaluable for MMc, 88 completed ITI, 18 were MMc positive (MMc+) and 70 were MMc negative (MMc-). Success was achieved in 75 (85.2%) patients, including 16 of 18 MMc+ patients (88.9%) and 59 of 70 MMc- patients (84.3%). Compared with MMc- patients, MMc+ patients had a lower peak inhibitor during ITI (median, 5.3 vs. 37.8 BU/ml, Conclusion: MMc was associated with more rapid ITI success in children with hemophilia A and inhibitors receiving low-dose ITI regimen, suggesting the potential role of MMc in facilitating the eradication of FVIII inhibitors.

Indexed as

Blood Coagulation Factor InhibitorsChimerismFactor VIIIHemophilia AImmune ToleranceAdolescentChildChild, PreschoolFemaleHumansInfantIsoantibodiesMaleRituximabBlood Coagulation Factor InhibitorsFactor VIIIIsoantibodiesRituximabFVIIIhemophilia Aimmune tolerance inductioninhibitormaternal microchimerism

Identifiers

PMID42712373
PMCPMC13549857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.